β-Amyloid aggregation induced by human acetylcholinesterase: Inhibition studies

Biochemical Pharmacology

Volumn 65, Issue 3, 2003, Pages 407-416

  Bartolini, Manuela ^a   Bertucci, Carlo ^a   Cavrini, Vanni ^a   Andrisano, Vincenza ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Amyloid (1 40); Acetylcholinesterase inhibitors; Alzheimer's disease; Fibrillogenesis; Human recombinant acetylcholinesterase; Mechanism of action

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; CHOLINESTERASE INHIBITOR; DECAMETHONIUM; DONEPEZIL; EDROPHONIUM; PHYSOSTIGMINE; PROPIDIUM IODIDE; TACRINE; THIOFLAVINE;

ALZHEIMER DISEASE; ARTICLE; CHOLINESTERASE INHIBITION; CIRCULAR DICHROISM; CONTROLLED STUDY; ENZYME INDUCTION; ENZYME KINETICS; FLUORESCENCE SPECTROSCOPY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN CONTENT;

ACETYLCHOLINESTERASE; AMYLOID BETA-PROTEIN; CHOLINESTERASE INHIBITORS; CIRCULAR DICHROISM; FLUOROMETRY; HUMANS; PEPTIDE FRAGMENTS; PROTEIN CONFORMATION; RECOMBINANT PROTEINS;

EID: 0037298750     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(02)01514-9     Document Type: Article

References (42)

1. Siddiqui M.F., Levey A.I. Cholinergic therapies in Alzheimer's disease. Drugs Fut. 24:1999;417-424.
2. Bartus R.T., Dean L.D. III, Beer B., Lippa A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science. 217:1982;408-417.
3. Reiner E, Radić Z. Mechanism of action of cholinesterase inhibitors. In: Giacobini E, editor. Cholinesterases and cholinesterase inhibitors. London: Martin Dunitz Ltd.; 2000. p. 103-19.
4. Inestrosa N.C., Alvarez A., Pérez C.A., Moreno R.D., Vicente M., Linker C., Casanueva O.I., Soto C., Garrido J. Acetylcholinesterase accelerates assembly of amyloid-β-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron. 16:1996;881-891.
5. Selkoe D.J. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature. 399:1999;A23-A31.
6. Alvarez A., Alarcon R., Opazo C., Campos E.O., Munoz F.J., Calderon F.H., Dajas F., Gentry M.K., Doctor B.P., De Mello F.G., Inestrosa N.C. Stable complexes involving acetylcholinesterase and amyloid-peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer's fibrils. J. Neurosci. 18:1998;3213-3223.
7. Selkoe D.J. Clearing the brain's amyloid cobwebs. Neuron. 32:2001;177-180.
8. Koo E.H., Lansbury P.T., Kelly J.W. Amyloid diseases: abnormal protein aggregation in neurodegeneration. Proc. Natl. Acad. Sci. U.S.A. 96:1999;9989-9990.
9. Selkoe D.J. Presenilin, notch and the genesis and treatment of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 98:2001;11039-11041.
10. De Ferrari G.V., Canales M.A., Shin I., Weiner L.M., Silman I., Inestrosa N.C. A structural motif of acetylcholinesterase that promotes amyloid β-peptide fibril formation. Biochemistry. 40:2001;10447-10457.
11. Harper J.D., Lieber C.M., Lansbury P.T. Atomic force microscopic imaging of seeded fibril formation and fibril branching by the Alzheimer's amyloid-beta protein. Chem. Biol. 4:1997;951-959.
12. Rochet J.C., Lansbury P.T. Jr. Amyloid fibrillogenesis: themes and variations. Curr. Opin. Struct. Biol. 10:2000;60-68.
13. Naiki H., Higuchi K., Nakakuki K., Takeda T. Kinetic analysis of amyloid fibril polymerization in vitro. Lab. Invest. 65:1991;104-110.
14. LeVine H. Thioflavin T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci. 2:1993;404-410.
15. LeVine H. III Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods Enzymol. 309:1999;274-284.
16. Ellman G.L., Courtney K.D., Andres V., Featherstone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7:1961;88-95.
17. Soto C., Castano E.M., Frangione B., Inestrosa N.C. The alpha-helical to beta-strand transition in the amino-terminal fragment of the amyloid beta-peptide modulates amyloid formation. J. Biol. Chem. 270:1995;3063-3067.
18. Hang S., Rich A. Direct conversion of an oligopeptide from a β-sheet to an α-helix: a model for amyloid formation. Proc. Natl. Acad. Sci. U.S.A. 94:1997;23-28.
19. Minor D.L., Kim P.S. Measurement of the β-sheet-forming propensities of amino acids. Nature. 367:1994;660-663.
20. Waterhous D.V., Johnson W.C. Jr. Importance of environment in determining secondary structure of in proteins. Biochemistry. 33:1994;2121-2128.
21. Manavalan P., Taylor P., Johnson W.C. Jr. Circular dichroism studies of acetylcholinesterase conformation: comparison of the 11 S and 5.6 S species and the differences induced by inhibitory ligands. Biochim. Biophys. Acta. 829:1985;365-370.
22. Fezoui Y., Hartley D.M., Harper J.D., Khurana R., Walsh D.M., Condron M.M., Selkoe D.J., Lansbury P.T. Jr., Fink A.L., Teplow D.B. An improved method of preparing the amyloid beta-protein for fibrillogenesis and neurotoxicity experiments. Amyloid. 7:2000;166-178.
23. Harper J.D., Wong S.S., Lieber C.M., Lansbury P.T. Jr. Assembly of A beta amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease. Biochemistry. 38:1999;8972-8980.
24. Giacobini E. Cholinesterase inhibitors: From the Calabar Bean to Alzheimer's therapy. In: Giacobini E, editor. Cholinesterases and Cholinesterase Inhibitors. London, UK: Martin Dunitz Ltd.; 2000. p. 181-226.
25. Melchiorre C., Andrisano V., Bolognesi M.L., Budriesi R., Cavalli A., Cavrini V., Rosini M., Tumiatti V., Recanatini M. Acetylcholinesterase noncovalent inhibitors based on a polyamine backbone for potential use against Alzheimer's disease. J. Med. Chem. 41:1998;4186-4189.
26. Ogura H., Kosasa T., Kuriya Y., Yamanishi Y. Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro. Methods Find Exp. Clin. Pharmacol. 22:2000;609-613.
27. Rampa A., Piazzi L., Belluti F., Gobbi S., Bisi A., Bartolini M., Andrisano V., Cavrini V., Cavalli A., Recanatini M., Valenti P. Acetylcholinesterase inhibitors: SAR and kinetic studies on omega-[N-methyl-N-(3-alkylcarbamoyloxyphenyl)methyl]aminoalkoxyaryl derivatives. J. Med. Chem. 44:2001;3810-3820.
28. Bolognesi M.L., Andrisano V., Bartolini M., Minarini A., Rosini M., Tumiatti V., Melchiorre C. Hexahydrochromeno [4,3-b] pyrrole derivatives as acetylcholinesterase inhibitors. J. Med. Chem. 44:2001;105-109.
29. Ariel N., Ordentlich A., Barak D., Bino T., Velan B., Shafferman A. The aromatic patch of three proximal residues in the human acetylcholinesterase active centre allows for versatile interaction modes with inhibitors. Biochem. J. 335:1998;95-102.
30. Harel M., Schalk I., Ehret-Sabatier L., Bouet F., Goeldner M., Hirth C., Axelsen P.H., Silman I., Sussman J.L. Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. Proc. Natl. Acad. Sci. U.S.A. 90:1993;9031-9035.
31. Taylor P., Lappi S. Interaction of fluorescence probes with acetylcholinesterase. The site and specificity of propidium binding. Biochemistry. 6:1975;1989-1997.
32. Eastman J., Wilson E.J., Cervenansky C., Rosenberry T.L. Fasciculin 2 binds to a peripheral site on acetylcholinesterase and inhibits substrate hydrolysis by slowing a step involving proton transfer during enzyme acylation. J. Biol. Chem. 270:1995;19694-19701.
33. Shigeta M., Homma A. Donepezil for Alzheimer's disease: pharmacodynamic, pharmacokinetic, and clinical profiles. CNS Drug Rev. 7:2001;353-368.
34. Barner E.L., Gray S.L. Donepezil use in Alzheimer's disease. Ann. Pharmacother. 32:1998;70-77.
35. Snape M.F., Misra A., Murray T.K., De Souza R.J., Williams J.L., Cross A.J., Green A.R. A comparative study in rats of the in vitro and in vivo pharmacology of the acetylcholinesterase inhibitors tacrine, donepezil and NXX-066. Neuropharmacology. 38:1999;181-193.
36. Cheng D.H., Tang X.C. Comparative studies of huperzine A, E2020, and tacrine on behavior and cholinesterase activities. Pharmacol. Biochem. Behav. 60:1998;377-386.
37. Main A.R., Hastings F.L. Carbamylation and binding constants for the inhibition of acetylcholinesterase by physostigmine. Science. 154:1966;400-402.
38. Mc Ilwain H, Bachelard HS. Biochemistry and the Central Nervous System. 5th Ed. New York, USA: Churchill Livingstone; 1985. p. 432-4.
39. Dominguez D.I., De Strooper B. Novel therapeutic strategies provide the real test for the amyloid hypothesis of Alzheimer's disease. Trends Pharmacol. Sci. 23:2002;324-330.
40. Reyes A.E., Perez D.R., Alvarez A., Garrido J., Gentry M.K., Doctor B.P., Inestrosa N.C. A monoclonal antibody against acetylcholinesterase inhibits the formation of amyloid fibrils induced by the enzyme. Biochem. Biophys. Res. Commun. 232(3):1997;652-655.
41. Valenti P., Rampa A., Bisi A., Fabbri G., Andrisano V., Cavrini V. Cholinergic agents: synthesis and acetylcholinesterase inhibitory activity of some ω-[N-methyl-N-(3-alkylcarbamoyloxyphenyl)methyl]aminoalkoxyxanthen-9- ones. Med. Chem. Res. 5:1995;255-264.
42. Rampa A., Bisi A., Valenti P., Recanatini M., Cavalli A., Andrisano V., Cavrini V., Fin L., Buriani A., Giusti P. Acetylcholinesterase inhibitors: synthesis and structure-activity relationships of ω-[N-methyl-N-(3-alkylcarbamoyloxyphenyl)-methyl]aminoalkoxyheteroaryl derivatives. J. Med. Chem. 41:1998;3976-3986.